Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Interest of Therapeutic Drug Monitoring of Immunosuppressants (Tacrolimus, Mycophenolate Mofetil) Based on Bayesian Estimation During the Three First Years Following Lung Transplantation, in Patients With or Without Cystic Fibrosis [Adaptation Bayésienne de posologie des immunosuppresseurs chez les patients transplantés pulmonaires, atteints ou non de mucoviscidose]

Trial Profile

Evaluation of the Interest of Therapeutic Drug Monitoring of Immunosuppressants (Tacrolimus, Mycophenolate Mofetil) Based on Bayesian Estimation During the Three First Years Following Lung Transplantation, in Patients With or Without Cystic Fibrosis [Adaptation Bayésienne de posologie des immunosuppresseurs chez les patients transplantés pulmonaires, atteints ou non de mucoviscidose]

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mycophenolate mofetil; Tacrolimus
  • Indications Lung transplant rejection
  • Focus Therapeutic Use
  • Acronyms BASALT

Most Recent Events

  • 28 Jun 2012 Astellas Pharma and Roche added as associations as reported in the European Clinical Trials Database record.
  • 02 May 2011 Status changed from recruiting to discontinued.
  • 26 Apr 2011 Biomarkers information updated

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top